178 related articles for article (PubMed ID: 27169683)
1. Selection of a discriminant and biorelevant in vitro dissolution test for the development of fenofibrate self-emulsifying lipid-based formulations.
Pestieau A; Krier F; Brouwers A; Streel B; Evrard B
Eur J Pharm Sci; 2016 Sep; 92():212-9. PubMed ID: 27169683
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
Fei Y; Kostewicz ES; Sheu MT; Dressman JB
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of different in vitro dissolution tests based on level A in vitro-in vivo correlations for fenofibrate self-emulsifying lipid-based formulations.
Pestieau A; Lebrun S; Cahay B; Brouwers A; Streel B; Cardot JM; Evrard B
Eur J Pharm Biopharm; 2017 Mar; 112():18-29. PubMed ID: 27865930
[No Abstract] [Full Text] [Related]
4. The conflict between in vitro release studies in human biorelevant media and the in vivo exposure in rats of the lipophilic compound fenofibrate.
Do TT; Van Speybroeck M; Mols R; Annaert P; Martens J; Van Humbeeck J; Vermant J; Augustijns P; Van den Mooter G
Int J Pharm; 2011 Jul; 414(1-2):118-24. PubMed ID: 21596119
[TBL] [Abstract][Full Text] [Related]
5. Gastrointestinal behavior of nano- and microsized fenofibrate: In vivo evaluation in man and in vitro simulation by assessment of the permeation potential.
Hens B; Brouwers J; Corsetti M; Augustijns P
Eur J Pharm Sci; 2015 Sep; 77():40-7. PubMed ID: 26004010
[TBL] [Abstract][Full Text] [Related]
6. Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: case studies with fenofibrate.
Griffin BT; Kuentz M; Vertzoni M; Kostewicz ES; Fei Y; Faisal W; Stillhart C; O'Driscoll CM; Reppas C; Dressman JB
Eur J Pharm Biopharm; 2014 Apr; 86(3):427-37. PubMed ID: 24184675
[TBL] [Abstract][Full Text] [Related]
7. Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles.
Juenemann D; Jantratid E; Wagner C; Reppas C; Vertzoni M; Dressman JB
Eur J Pharm Biopharm; 2011 Feb; 77(2):257-64. PubMed ID: 21074611
[TBL] [Abstract][Full Text] [Related]
8. Mesoporous silica-based dosage forms improve release characteristics of poorly soluble drugs: case example fenofibrate.
Dressman JB; Herbert E; Wieber A; Birk G; Saal C; Lubda D
J Pharm Pharmacol; 2016 May; 68(5):634-45. PubMed ID: 26255860
[TBL] [Abstract][Full Text] [Related]
9. Dynamic dissolution-/permeation-testing of nano- and microparticle formulations of fenofibrate.
Sironi D; Rosenberg J; Bauer-Brandl A; Brandl M
Eur J Pharm Sci; 2017 Jan; 96():20-27. PubMed ID: 27597143
[TBL] [Abstract][Full Text] [Related]
10. Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments.
O'Shea JP; Faisal W; Ruane-O'Hora T; Devine KJ; Kostewicz ES; O'Driscoll CM; Griffin BT
Eur J Pharm Biopharm; 2015 Oct; 96():207-16. PubMed ID: 26215636
[TBL] [Abstract][Full Text] [Related]
11. Combining in vitro and in silico methods for better prediction of surfactant effects on the absorption of poorly water soluble drugs-a fenofibrate case example.
Berthelsen R; Sjögren E; Jacobsen J; Kristensen J; Holm R; Abrahamsson B; Müllertz A
Int J Pharm; 2014 Oct; 473(1-2):356-65. PubMed ID: 24997410
[TBL] [Abstract][Full Text] [Related]
12. The in vitro and in vivo evaluation of fenofibrate with a self- microemulsifying formulation.
Xiumin LI; Man GE; Minzi LU; Yinghua J; Dongqin Q
Curr Drug Deliv; 2015; 12(3):308-13. PubMed ID: 26054534
[TBL] [Abstract][Full Text] [Related]
13. Dissolution improvement of solid self-emulsifying drug delivery systems of fenofibrate using an inorganic high surface adsorption material.
Shazly G; Mohsin K
Acta Pharm; 2015 Mar; 65(1):29-42. PubMed ID: 25781702
[TBL] [Abstract][Full Text] [Related]
14. Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation.
Suys EJA; Chalmers DK; Pouton CW; Porter CJH
Mol Pharm; 2018 Jun; 15(6):2355-2371. PubMed ID: 29659287
[TBL] [Abstract][Full Text] [Related]
15. In vitro dissolution models for the prediction of in vivo performance of an oral mesoporous silica formulation.
McCarthy CA; Faisal W; O'Shea JP; Murphy C; Ahern RJ; Ryan KB; Griffin BT; Crean AM
J Control Release; 2017 Mar; 250():86-95. PubMed ID: 28132935
[TBL] [Abstract][Full Text] [Related]
16. Solid self-emulsifying drug delivery system (S-SEDDS) for improved dissolution rate of fenofibrate.
Kanaujia P; Ng WK; Tan RB
J Microencapsul; 2014; 31(3):293-8. PubMed ID: 24156747
[TBL] [Abstract][Full Text] [Related]
17. Design of lipid-based formulations for oral administration of poorly water-soluble drug fenofibrate: effects of digestion.
Mohsin K
AAPS PharmSciTech; 2012 Jun; 13(2):637-46. PubMed ID: 22547370
[TBL] [Abstract][Full Text] [Related]
18. Developing Quantitative In Vitro-In Vivo Correlation for Fenofibrate Immediate-Release Formulations With the Biphasic Dissolution-Partition Test Method.
Xu H; Shi Y; Vela S; Marroum P; Gao P
J Pharm Sci; 2018 Jan; 107(1):476-487. PubMed ID: 28666964
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo evaluation of a self-microemulsifying drug delivery system for the poorly soluble drug fenofibrate.
Cho YD; Park YJ
Arch Pharm Res; 2014 Feb; 37(2):193-203. PubMed ID: 23754165
[TBL] [Abstract][Full Text] [Related]
20. Selection of excipient, solvent and packaging to optimize the performance of spray-dried formulations: case example fenofibrate.
Hugo M; Kunath K; Dressman J
Drug Dev Ind Pharm; 2013 Feb; 39(2):402-12. PubMed ID: 22591213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
